Control of lupus activity during pregnancy via the engagement of IgG sialylation: novel crosstalk between IgG sialylation and pDC functions

[1]  F. Houssiau,et al.  IFN-α kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study , 2019, Annals of the rheumatic diseases.

[2]  V. Pascual,et al.  Longitudinal profiling of human blood transcriptome in healthy and lupus pregnancy , 2019, The Journal of experimental medicine.

[3]  M. Perola,et al.  Low galactosylation of IgG associates with higher risk for future diagnosis of rheumatoid arthritis during 10 years of follow-up. , 2018, Biochimica et biophysica acta. Molecular basis of disease.

[4]  Mimi Y. Kim,et al.  Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies , 2018, Annals of the rheumatic diseases.

[5]  G. Mor,et al.  The unique immunological and microbial aspects of pregnancy , 2017, Nature Reviews Immunology.

[6]  G. Alter,et al.  The Immunoregulatory Roles of Antibody Glycosylation. , 2017, Trends in immunology.

[7]  S. Way,et al.  Type I interferons regulate susceptibility to inflammation-induced preterm birth. , 2017, JCI insight.

[8]  Mark B. Jones,et al.  B-cell–independent sialylation of IgG , 2016, Proceedings of the National Academy of Sciences.

[9]  M. Melbye,et al.  Association Between Use of Oral Fluconazole During Pregnancy and Risk of Spontaneous Abortion and Stillbirth. , 2016, JAMA.

[10]  R. Ahmed,et al.  Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficacy , 2015, Cell.

[11]  T. Spector,et al.  Association of Systemic Lupus Erythematosus With Decreased Immunosuppressive Potential of the IgG Glycome , 2015, Arthritis & rheumatology.

[12]  Y. Crow,et al.  Aicardi–Goutières syndrome and the type I interferonopathies , 2015, Nature Reviews Immunology.

[13]  R. Maciuca,et al.  A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE) , 2015, Annals of the rheumatic diseases.

[14]  Mimi Kim,et al.  Interferon‐α and Angiogenic Dysregulation in Pregnant Lupus Patients Who Develop Preeclampsia , 2015, Arthritis & rheumatology.

[15]  C. Nelson-Piercy,et al.  High-risk pregnancy and the rheumatologist. , 2015, Rheumatology.

[16]  Gillian Dekkers,et al.  IgG Subclasses and Allotypes: From Structure to Effector Functions , 2014, Front. Immunol..

[17]  C. Rice,et al.  Interferon-stimulated genes: a complex web of host defenses. , 2014, Annual review of immunology.

[18]  K. Kirou,et al.  Anti-interferon alpha treatment in SLE. , 2013, Clinical immunology.

[19]  M. Ehlers,et al.  The carbohydrate switch between pathogenic and immunosuppressive antigen‐specific antibodies , 2013, Experimental dermatology.

[20]  J. Ravetch,et al.  Intravenous gammaglobulin suppresses inflammation through a novel TH2 pathway , 2011, Nature.

[21]  B. Reizis,et al.  Plasmacytoid dendritic cells: recent progress and open questions. , 2011, Annual review of immunology.

[22]  W. Cao,et al.  Signaling and ligand interaction of ILT7: receptor‐mediated regulatory mechanisms for plasmacytoid dendritic cells , 2010, Immunological reviews.

[23]  L. Cavacini,et al.  Structure and function of immunoglobulins. , 2010, The Journal of allergy and clinical immunology.

[24]  M. Gilliet,et al.  Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases , 2008, Nature Reviews Immunology.

[25]  E. Myers,et al.  A national study of the complications of lupus in pregnancy. , 2008, American journal of obstetrics and gynecology.

[26]  Robert M. Anthony,et al.  Recapitulation of IVIG Anti-Inflammatory Activity with a Recombinant IgG Fc , 2008, Science.

[27]  M. Clowse.  Lupus activity in pregnancy. , 2007, Rheumatic diseases clinics of North America.

[28]  A. Marshak‐Rothstein.  Toll-like receptors in systemic autoimmune disease , 2006, Nature Reviews Immunology.

[29]  J. Thurman,et al.  Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction , 2006, The Journal of experimental medicine.

[30]  D. Furst,et al.  Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus. , 2006, Arthritis and rheumatism.

[31]  J. Ravetch,et al.  Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation , 2006, Science.

[32]  Wei Cao,et al.  Plasmacytoid dendritic cell–specific receptor ILT7–FcɛRIγ inhibits Toll-like receptor–induced interferon production , 2006, The Journal of experimental medicine.

[33]  L. Magder,et al.  The impact of increased lupus activity on obstetric outcomes. , 2005, Arthritis and rheumatism.

[34]  M. Khamashta,et al.  Evaluation of systemic lupus erythematosus activity during pregnancy , 2004, Lupus.

[35]  Virginia Pascual,et al.  Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood , 2003, The Journal of experimental medicine.

[36]  G. Karypis,et al.  Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[37]  R. Dwek,et al.  Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG , 1985, Nature.

[38]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.